Regeneron Pharmaceuticals (WBO:REGN) Inventories, Finished Goods : €166 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Inventories, Finished Goods?

Regeneron Pharmaceuticals's quarterly finished goods increased from Sep. 2023 (€107 Mil) to Dec. 2023 (€135 Mil) and increased from Dec. 2023 (€135 Mil) to Mar. 2024 (€166 Mil).

Regeneron Pharmaceuticals's annual finished goods increased from Dec. 2021 (€65 Mil) to Dec. 2022 (€93 Mil) and increased from Dec. 2022 (€93 Mil) to Dec. 2023 (€135 Mil).

Regeneron Pharmaceuticals Inventories, Finished Goods Historical Data

The historical data trend for Regeneron Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Inventories, Finished Goods Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

63.54

100.04

65.23

93.08

135.07

Regeneron Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															158.13	115.65	107.01	135.07	166.06

Regeneron Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Regeneron Pharmaceuticals (WBO:REGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico RGO:Germany REGN34:Brazil

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).